TAIPEI, Taiwan – At BioBusiness Asia 2016, a two-day conference and part of the four-day BioTaiwan festival, sessions on drug development models and global partnering strategies showcased several Taiwanese companies that have succeeded by adopting strategies tailor-made for Taiwan conditions.

While debate continues around how much biopharma innovation is actually taking place in Asia, Taiwan is pitching itself as an underexplored location where innovation is available for those who take the time and effort to uncover it.

TAIPEI, Taiwan – In recent years, Taiwan has been pouring considerable attention, effort and funding into the development of a sustainable biotech industry, seeking a new economic driver to replace the diminishing prominence of its once-dominant electronics manufacturing sector.

TAIPEI, Taiwan – While debate continues around how much biopharma innovation is actually taking place in Asia, Taiwan is pitching itself as an underexplored location where innovation is available for those who take the time and effort to uncover it.

TAIPEI, Taiwan – In recent years, Taiwan has been pouring considerable attention, effort and funding into the development of a sustainable biotech industry, seeking a new economic driver to replace the diminishing prominence of its once-dominant electronics manufacturing sector.

TAIPEI, Taiwan – Taiwan's media and capital markets overlooked the positives from OBI Pharma Inc.'s recently reported top-line results from its global phase II/III trial of the OBI-822/821 active immunotherapy for metastatic breast cancer, which missed its primary endpoints, according to Michael Chang, chairman of the Taipei-headquartered company.

TAIPEI, Taiwan – Taiwan's media and capital markets overlooked the positives from OBI Pharma Inc.'s recently reported top-line results from its global phase II/III trial of the OBI-822/821 active immunotherapy for metastatic breast cancer, which missed its primary endpoints, according to Michael Chang, chairman of the Taipei-headquartered company.

As a small country, New Zealand has always needed to punch above its weight to be noticed, whether in sports, entertainment or science. With its rugby team the All Blacks recent winners of the Rugby World Cup, and the global success of the "Lord of the Rings" and "The Hobbit" film trilogies, there's another area where New Zealand is overachieving considering its population of just 4 million: cancer immunotherapy.

TAIPEI, Taiwan – Taipei-based OBI Pharma Inc. has entered a deal with Merck & Co. Inc., of Kenilworth, N.J., for the development and commercialization in Taiwan of its narrow-spectrum macrocyclic antibiotic Dificid (fidaxomicin), which is used to treat Clostridium difficile-associated diarrhea (CDAD). The collaboration represents a long-awaited milestone for OBI as its first major revenue-stream generating deal since its formation in 2002.